C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524686-24-00

Enrollment

Registered

2026-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Brief summary

Confirmed ORR as assessed by investigator based on RECIST v1.1, AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Detailed description

DOR as assessed by investigator based on RECIST v1.1, PFS as assessed by investigator based on RECIST v1.1, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and postdose concentrations of PF-08634404., Incidence of ADA against PF-08634404.

Interventions

DRUGCARBOPLATIN

DRUGETOPOSIDE

DRUGPF-08634404

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Confirmed ORR as assessed by investigator based on RECIST v1.1, AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.	—

Secondary

Measure	Time frame
DOR as assessed by investigator based on RECIST v1.1, PFS as assessed by investigator based on RECIST v1.1, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and postdose concentrations of PF-08634404., Incidence of ADA against PF-08634404.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 30, 2026